📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Seamec Limited Reports Record Q3 FY26 Results with 138% Revenue Growth and ₹100 Cr PAT
Seamec Limited achieved its highest-ever quarterly revenue and profitability in Q3 FY26, driven by record vessel deployment and efficient execution. Consolidated revenue surged 138% YoY to ₹331 crore, while PAT turned around from a loss to a profit of ₹100 crore. The company is in the process of acquiring the vessel 'Anant,' expected to be deployed in Q1 FY27, which will further boost growth. Management maintains a strong balance sheet with zero net debt and expects sustained demand in the offshore energy services sector.
Key Highlights
Consolidated revenue grew by 138% YoY to ₹331 crore in Q3 FY26
EBITDA reached ₹150 crore compared to ₹34 crore in the previous year's quarter
Reported a PAT of ₹100 crore, a significant recovery from a ₹3 crore loss in Q3 FY25
Vessel 'Swordfish' commands a high day rate of $75,000, contributing to margin expansion
Acquisition of vessel 'Anant' to be completed this fiscal, with deployment scheduled for Q1 FY27
💼 Action for Investors
Investors should view the strong earnings turnaround and high asset utilization as a positive sign of operational efficiency. The zero net-debt status and upcoming vessel additions provide a clear growth trajectory for the next financial year.
Alembic Pharma Q3 FY26 Revenue Up 11% to INR 18.76 Bn; Ex-US Generics Surges 36%
Alembic Pharmaceuticals reported a steady Q3 FY26 with revenue growing 11% YoY to INR 18.76 billion, driven largely by a 36% surge in Ex-US Generics. While EBITDA grew 14% to INR 3.08 billion, the bottom line was impacted by a one-time exceptional loss of INR 0.42 billion, leading to a slight 4% dip in PAT to INR 1.33 billion. The India Branded and US Generics segments showed moderate growth of 6% each, while the Animal Health division performed strongly with 22% growth. R&D investments remained significant at 9% of revenue, supporting a pipeline of 270 ANDA filings.
Key Highlights
Total Revenue increased 11% YoY to INR 18.76 billion in Q3 FY26.
Ex-US Generics revenue reached an all-time high of INR 4.06 billion, growing 36% YoY.
EBITDA margins stood at 16%, with EBITDA growing 14% YoY to INR 3.08 billion.
India Branded Business grew 6% to INR 6.52 billion, maintaining a 21st rank in the Indian Pharmaceutical Market.
R&D expenditure increased to INR 1.65 billion, representing 9% of total revenue.
💼 Action for Investors
Investors should take note of the strong momentum in Ex-US Generics and Animal Health, which are effectively diversifying the company's revenue streams. The core India and US businesses remain stable, though the impact of one-time exceptional items on the net profit should be monitored.
Borosil Q3 FY26 Net Profit Drops 32.5% YoY to ₹23.95 Cr; Revenue Stagnant at ₹338.7 Cr
Borosil Limited reported a weak set of numbers for Q3 FY26, with consolidated net profit declining 32.5% YoY to ₹23.95 crore. Revenue from operations remained nearly flat at ₹338.75 crore compared to ₹338.10 crore in the previous year's corresponding quarter. Profitability was further dampened by a one-time exceptional expense of ₹4.05 crore related to the implementation of new Labour Codes. While the nine-month revenue shows a growth of 8.8%, the bottom line remains stagnant, indicating significant margin pressure.
Key Highlights
Consolidated Net Profit fell 32.5% YoY to ₹2,395.14 lakhs in Q3 FY26.
Revenue from operations was stagnant at ₹33,874.68 lakhs compared to ₹33,810.29 lakhs YoY.
Recognized a one-time exceptional charge of ₹404.82 lakhs due to new Government Labour Codes.
9M FY26 Revenue grew 8.8% to ₹91,179.65 lakhs, while 9M PAT remained flat at ₹6,407.54 lakhs.
Consolidated Basic EPS for the quarter decreased to ₹2.00 from ₹2.97 in Q3 FY25.
💼 Action for Investors
Investors should exercise caution as the company faces stagnant revenue growth and margin contraction. The stock may face near-term pressure until there is clarity on demand recovery in the consumerware segment.
Borosil Q3 FY26 Net Profit Drops 32.5% YoY to ₹23.95 Cr; Revenue Flat at ₹338.7 Cr
Borosil Limited reported a stagnant revenue performance for Q3 FY26, with consolidated revenue from operations at ₹338.75 crore compared to ₹338.10 crore in the previous year. Consolidated Net Profit witnessed a sharp decline of 32.5% YoY, falling to ₹23.95 crore from ₹35.48 crore, largely due to increased procurement costs and a one-time exceptional charge. The company recognized an exceptional expense of ₹4.05 crore related to the implementation of new Labour Codes. While revenue was flat YoY, the company managed a slight sequential (QoQ) improvement in net profit from ₹22.71 crore in Q2 FY26.
Key Highlights
Consolidated Revenue from Operations remained nearly flat at ₹338.75 crore vs ₹338.10 crore YoY.
Net Profit for the quarter fell 32.5% YoY to ₹23.95 crore, down from ₹35.48 crore.
Recognized a one-time exceptional expense of ₹404.82 lakhs due to the consolidation of Indian Labour Codes.
Purchases of stock-in-trade rose significantly to ₹120.64 crore from ₹89.19 crore in the year-ago period.
Basic EPS for the quarter declined to ₹2.00 from ₹2.97 in Q3 FY25.
💼 Action for Investors
Investors should monitor the impact of rising procurement costs on margins, as stagnant revenue growth coupled with higher expenses has pressured the bottom line. The stock may face short-term pressure following this significant drop in profitability.
Oberoi Realty Clarifies Rs 5,400 Cr Bid for 11-Acre Bandra Land Lease
Oberoi Realty has provided a detailed breakdown of its Rs 5,400 crore bid for an 11-acre land parcel in Bandra East, Mumbai, from the Railway Land Development Authority (RLDA). The bid amount is the Net Present Value (NPV) of payments, with an initial cash outflow of Rs 495 crore within 150 days. The remaining Rs 4,905 crore NPV will be paid through a 45% revenue-sharing model until 2038, using a discount rate of 10.75%. This prime location offers a massive development potential of 19.50 lakh sq. ft. over a 99-year lease period.
Key Highlights
Total bid of Rs 5,400 crore (NPV) for 99-year lease of 45,371 sq. mt. land in Bandra East
Initial payment of Rs 495 crore to be made within 150 days of RLDA demand letter
Balance NPV of Rs 4,905 crore to be settled via 45% share of gross revenues till 2038
Project offers significant FSI potential of approximately 19.50 lakh sq. ft.
Company to bear all development and construction costs in addition to the lease payments
💼 Action for Investors
This is a major strategic acquisition in a high-demand Mumbai micro-market; investors should monitor the project's launch timeline and its impact on the company's debt-to-equity ratio.
Alembic Pharma Q3 FY26 Revenue Up 11% to ₹1,876 Cr; Ex-US Generics Surge 36%
Alembic Pharmaceuticals reported a steady 11% YoY revenue growth for Q3 FY26, reaching ₹1,876 Cr, driven by a robust 36% surge in Ex-US international generics. EBITDA grew 14% to ₹308 Cr with margins at 16%, although reported PAT of ₹133 Cr was impacted by a one-time ₹42 Cr provision for labor code changes. The company maintained high R&D investment at 9% of revenue and is preparing for the launch of PivyaTM in the US market during Q4. Core segments like India Branded and US Generics showed modest growth of 6% each.
Key Highlights
Revenue from operations increased 11% YoY to ₹1,876 Cr with EBITDA rising 14% to ₹308 Cr.
Ex-US International Generics business outperformed with 36% growth, reaching ₹406 Cr.
Reported PAT stood at ₹133 Cr after accounting for a ₹42 Cr one-time provision for employee benefits.
R&D expenditure remains significant at 9% of revenue to support a pipeline of 232 cumulative ANDA approvals.
India Branded Business grew 6% to ₹652 Cr, supported by Gynaecology and Ophthalmology segments.
💼 Action for Investors
Investors should look past the one-time labor provision and focus on the strong momentum in international markets and the upcoming branded product launch in the US. The stock remains a solid play on diversified pharmaceutical growth with a healthy R&D pipeline.
Alembic Pharma Q3 FY26: International Revenue Up 17% YoY to ₹954 Cr, Animal Health Grows 22%
Alembic Pharmaceuticals reported a steady Q3 FY26 with total international generic sales growing 17% YoY to ₹954 crore, driven by strong performance in Australia (65%) and Canada (32%). The US market saw a modest 6% growth to ₹553 crore, supported by new launches like Sacubitril Valsartan. Domestic branded formulations grew 6% YoY to ₹652 crore, with the Animal Health segment showing robust growth of 22%. The company continues its R&D momentum with 5 ANDA filings YTD and 7 launches planned for Q4 FY26.
Key Highlights
International Generics revenue grew 17% YoY to ₹954 Cr, with Australia and EROW segments leading growth at 65% and 36% respectively.
US Direct sales reached ₹478 Cr, a 7% YoY increase, aided by new product launches like Ticagrelor and Metoprolol.
Domestic Branded Formulations grew 6% YoY to ₹652 Cr, significantly bolstered by a 22% surge in the Animal Health business.
API business remained relatively flat with 2% YoY growth, totaling ₹263 Cr for the quarter.
Strong R&D pipeline with 212 cumulative final ANDA approvals and 7 new products planned for launch in Q4 FY26.
💼 Action for Investors
Investors should monitor the ramp-up of new US launches and the continued outperformance of the Animal Health segment. The steady growth in EROW markets provides a good hedge against US pricing pressures.
Alembic Pharma Q3 FY26: Revenue Grows 11% YoY to ₹1,876 Cr; PAT Impacted by Exceptional Item
Alembic Pharmaceuticals reported a steady 10.8% year-on-year growth in consolidated revenue to ₹1,876.31 crore for the quarter ended December 31, 2025. Reported net profit for the quarter stood at ₹132.97 crore, a slight decline from ₹138.42 crore in the previous year, primarily due to a one-time exceptional charge of ₹42.23 crore related to new Labour Code provisions. Excluding this exceptional item, the Profit Before Tax (PBT) showed robust growth of 14.6% YoY, reaching ₹203.73 crore. The company also announced the transition of Mr. Rajkumar Baheti to a Non-Executive Director role effective April 2026.
Key Highlights
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.
Profit Before Tax (before exceptional items) grew 14.6% YoY to ₹203.73 crore.
Net Profit after tax stood at ₹132.97 crore, impacted by a ₹42.23 crore one-time provision for labour code compliance.
Operating Margin (EBITDA before exceptional items) was reported at 16.42% for the quarter.
Debt-to-Equity ratio remains stable and healthy at 0.25x as of December 31, 2025.
💼 Action for Investors
Investors should look past the reported PAT decline as it was caused by a non-recurring regulatory provision; the core operational PBT growth of 14.6% is a better indicator of performance. The company remains a steady hold given its consistent revenue growth and strong balance sheet.
Alembic Pharma Q3 Revenue Up 11% YoY to ₹1,876 Cr; PAT Impacted by ₹42 Cr Exceptional Item
Alembic Pharmaceuticals reported a 10.8% YoY growth in consolidated revenue for Q3 FY26, reaching ₹1,876.31 crore. However, Net Profit for the quarter declined slightly to ₹132.97 crore from ₹138.42 crore in the previous year, primarily due to a one-time exceptional charge of ₹42.23 crore related to the new Labour Code provisions. On a nine-month basis, the company performed better with revenue growing 12% to ₹5,497.18 crore. The board also approved the appointment of Mr. Rajkumar Baheti as a Non-Executive Director effective April 2026.
Key Highlights
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.
Net Profit after non-controlling interests stood at ₹132.97 crore, down 3.9% YoY due to exceptional items.
A one-time exceptional expense of ₹42.23 crore was recognized for gratuity and wage revisions under new Labour Codes.
Operating Margin (EBITDA before exceptional items) for the quarter was 16.42%.
Debt-Equity ratio remains healthy at 0.25x with a Net Worth of ₹5,463.32 crore.
💼 Action for Investors
Investors should look past the one-time labour code expense to the steady 11% top-line growth, though the sequential decline in margins requires monitoring. The stock remains a hold for those focused on long-term pharmaceutical sector recovery.
Voltamp Transformers Q3 Net Sales Up 30% YoY; New Orders Worth ₹1,981 Cr Secured
Voltamp Transformers reported a robust Q3 FY26 with Net Sales growing 30% YoY to ₹630.32 crore and Net Profit before Tax increasing 27% to ₹129.88 crore. The company has secured substantial new orders worth ₹1,981 crore since April 2025, maintaining a selective approach to protect margins. Construction of the new greenfield EHV Power Transformer facility is on track for completion by June 2026, with ₹124.22 crore already invested. While demand remains strong from power utilities, management flagged concerns regarding rising copper prices and currency volatility impacting raw material costs.
Key Highlights
Q3 Net Sales and Services Income grew 30% YoY to ₹630.32 crore compared to ₹483.52 crore.
Net Profit before Tax for Q3 rose 27% YoY to ₹129.88 crore.
Secured new orders worth ₹1,981 crore (16,768 MVA) during the current fiscal year starting April 2025.
Greenfield EHV manufacturing facility on track for June 2026 completion with ₹124.22 crore spent to date.
9-month Net Sales reached ₹1,536.46 crore, representing a 17% increase over the previous year.
💼 Action for Investors
Investors should take confidence in the strong revenue growth and healthy order pipeline driven by infrastructure demand. However, keep a close watch on margin sustainability given the management's warning on rising copper prices and USD strength.
Voltamp Transformers Q3 Net Profit Jumps 35% YoY to ₹99.08 Crore
Voltamp Transformers reported a robust performance for Q3 FY26, with revenue from operations growing 30.3% year-on-year to ₹630.32 crore. Net profit for the quarter rose by 35% to ₹99.08 crore compared to ₹73.40 crore in the same period last year. The company maintained strong operational momentum despite a one-time provision of ₹5.17 crore related to new labour code regulations. For the nine-month period ending December 2025, the company achieved a net profit of ₹257.48 crore, reflecting steady demand in the electrical equipment sector.
Key Highlights
Revenue from operations increased 30.3% YoY to ₹63,032.32 lakhs in Q3 FY26.
Net profit grew by 35% YoY to ₹9,908.26 lakhs from ₹7,340.24 lakhs.
Basic EPS for the quarter improved significantly to ₹97.94 from ₹72.55 YoY.
Other income surged to ₹2,614.16 lakhs, providing a substantial boost to the bottom line.
Company accounted for a ₹517.18 lakh provision due to the implementation of new Labour Codes.
💼 Action for Investors
The company continues to benefit from the power sector's expansion, showing strong top-line and bottom-line growth. Investors should maintain their positions as the company demonstrates efficient execution and healthy margins.
Voltamp Transformers Q3 Net Profit Jumps 35% YoY to ₹99.08 Crore
Voltamp Transformers reported a strong performance for Q3 FY26, with revenue from operations growing 30.4% YoY to ₹630.32 crore. Net profit for the quarter rose significantly by 35% YoY to ₹99.08 crore, even after accounting for a one-time provision of ₹5.17 crore related to new labour codes. The nine-month profit also showed healthy growth, reaching ₹257.48 crore compared to ₹228.59 crore in the previous year. The company continues to maintain a strong balance sheet with zero debt and improved EPS of ₹97.94.
Key Highlights
Revenue from operations increased by 30.4% YoY to ₹630.32 crore in Q3 FY26.
Net Profit grew by 35% YoY to ₹99.08 crore, up from ₹73.40 crore in Q3 FY25.
Earnings Per Share (EPS) for the quarter rose to ₹97.94 from ₹72.55 in the previous year.
Nine-month total income reached ₹1,613.06 crore, reflecting steady industrial demand.
Company made a provision of ₹517.18 lakhs due to the implementation of new Labour Codes effective Nov 2025.
💼 Action for Investors
The results indicate robust demand in the power equipment sector and strong operational execution. Investors should maintain a positive outlook as the company remains a key beneficiary of India's power infrastructure expansion.
Max Healthcare Q3 Revenue Up 10% to ₹2,608 Cr; PAT Grows 9% to ₹344 Cr
Max Healthcare reported a steady Q3 FY26 with gross revenue rising 10% YoY to ₹2,608 Cr, supported by a 7% growth in occupied bed days. Network Operating EBITDA grew 4% YoY to ₹648 Cr, though margins saw a slight compression to 26.1% due to pre-commissioning expenses and regulatory shifts. PAT increased 9% YoY to ₹344 Cr, even after accounting for ₹55 Cr in exceptional items related to labor codes and stamp duties. The company is actively expanding, having commissioned new beds in Mohali and Mumbai while announcing a new 450-bed project in Pune.
Key Highlights
Gross Revenue grew 10% YoY to ₹2,608 Cr; Network PAT increased 9% YoY to ₹344 Cr.
ARPOB improved to ₹77.9k from ₹75.9k YoY, while bed occupancy stood at 74%.
Successfully commissioned 53 beds in Mohali and 63 beds in Nanavati Max with healthy initial margins of 39% and 31% respectively.
Announced staggered acquisition of Yerawada Properties in Pune for a new ~450-bed hospital project.
Exceptional charges of ₹55 Cr impacted the bottom line, alongside temporary headwinds from CGHS tariff revisions and drug pricing guidelines.
💼 Action for Investors
Investors should monitor the ramp-up of newly commissioned brownfield beds which are already delivering accretive margins. The company's aggressive expansion into Pune and Delhi NCR reinforces its long-term growth trajectory in the premium healthcare segment.
Max Healthcare Q3 Revenue Grows 10% to ₹2,608 Cr; PAT Up 9% to ₹344 Cr
Max Healthcare reported a steady Q3 FY26 with a 10% YoY revenue growth to ₹2,608 Cr and a 9% rise in PAT to ₹344 Cr, despite ₹55 Cr in exceptional charges. Operating margins compressed slightly to 26.1% from 27.3% due to pre-commissioning expenses for new beds and regulatory impacts on institutional drug pricing. The company is aggressively expanding, with new brownfield beds already operational in Mohali and Nanavati showing strong initial margins. Operational metrics remain healthy with ARPOB increasing to ₹77.9k and bed occupancy at 74%.
Key Highlights
Gross Revenue grew 10% YoY to ₹2,608 Cr, while Network Operating EBITDA rose 4% YoY to ₹648 Cr.
PAT increased 9% YoY to ₹344 Cr after accounting for ₹55 Cr in exceptional items related to wage codes and stamp duty.
ARPOB (Average Revenue Per Occupied Bed) improved to ₹77.9k, while bed occupancy stood at 74%.
Newly commissioned beds in Mohali (53 beds) and Nanavati (63 beds) delivered healthy EBITDA margins of 39% and 31% respectively.
Announced a new 450-bed hospital project in Pune via the acquisition of Yerawada Properties Pvt. Ltd.
💼 Action for Investors
Investors should view the slight margin compression as temporary due to expansion costs, while focusing on the strong performance of newly commissioned beds. The company's aggressive capacity addition and entry into the Pune market provide a clear roadmap for long-term growth.
Max Healthcare Q3 PAT Rises 26% YoY to ₹301 Cr; Dwarka Hospital Expansion Approved
Max Healthcare Institute reported a steady performance for Q3 FY26 with consolidated revenue growing 10.7% YoY to ₹2,067.5 crore. Net profit (PAT) saw a robust 26% YoY increase to ₹300.9 crore, despite an exceptional charge of ₹48.2 crore during the quarter. The company is aggressively pursuing growth, evidenced by the board's approval to add ~260 beds to its Dwarka facility, nearly doubling its current 300-bed capacity. While sequential (QoQ) performance showed a slight dip in revenue and profit, the nine-month PAT growth of 45% YoY highlights strong operational momentum.
Key Highlights
Consolidated Revenue from operations increased 10.7% YoY to ₹2,06,752 Lakhs.
Net Profit (PAT) for the quarter rose 26% YoY to ₹30,092 Lakhs from ₹23,880 Lakhs.
Board approved expansion of Max Super Speciality Hospital, Dwarka by adding ~260 additional beds.
Nine-month (9M FY26) PAT reached ₹1,10,019 Lakhs, a 45% increase over the previous year's ₹75,688 Lakhs.
Exceptional item of ₹4,824 Lakhs recorded in Q3 FY26, impacting the pre-tax profit.
💼 Action for Investors
Investors should remain positive on the stock given the strong YoY earnings growth and the clear roadmap for capacity expansion in high-demand areas like Dwarka. The long-term outlook remains healthy as the company scales its bed capacity and maintains double-digit revenue growth.
UltraTech Cement Targets 194 MTPA Capacity by 2028; FY25 Revenue Hits $8.9 Billion
UltraTech Cement has released an updated corporate dossier outlining its path to becoming a 194.06 MTPA capacity player by 2028. As of December 2025, the company maintains a market capitalization of approximately USD 38.6 billion and reported FY25 consolidated revenues of USD 8.9 billion. The growth strategy relies on significant inorganic expansions, including the acquisitions of India Cements (14.45 MTPA) and Kesoram (10.75 MTPA). Additionally, its Ready Mix Concrete (RMC) business has scaled to 425 plants, contributing Rs 6,170 crore in revenue during FY25.
Key Highlights
Targeting a total cement capacity of 194.06 MTPA by 2028 through organic and inorganic routes.
Consolidated revenue for FY25 reached approximately USD 8.9 billion with 2.7 billion bags of cement sold annually.
RMC segment revenue stood at Rs 6,170 crore in FY25, supported by a network of 425 plants.
Retail footprint expanded to 5,290 UltraTech Building Solutions outlets across 23 Indian states.
Major recent acquisitions include India Cements (14.45 MTPA) and Kesoram (10.75 MTPA) to solidify market leadership.
💼 Action for Investors
Investors should maintain a positive outlook on UltraTech as it consolidates its leadership through aggressive capacity additions and diversification into high-margin building products. Monitor the execution of the 194 MTPA roadmap and the integration of the India Cements acquisition for potential synergy benefits.
MPS Ltd Finalizes Funding for $16.5M Acquisition of Unbound Medicine via Debt and Accruals
MPS Limited has outlined a comprehensive funding structure for its USD 16.50 million acquisition of Unbound Medicine, Inc. The acquisition will be financed through a mix of internal accruals, inter-company loans totaling USD 4.94 million, and a new INR 420 million term loan from ICICI Bank. The company is infusing USD 9.81 million as equity into its US subsidiary, MPS North America LLC, to facilitate the transaction. This structured financing ensures the acquisition proceeds without diluting the parent company's 100% stake in its US operations.
Key Highlights
Total acquisition consideration for Unbound Medicine, Inc. is USD 16.50 million.
Secured an INR 420 million term loan from ICICI Bank at a competitive interest rate of 7.85%.
Inter-company loans of USD 3.00 million and USD 1.94 million arranged to optimize group liquidity.
MPS Limited to infuse USD 9.81 million in equity into its wholly-owned subsidiary MPS North America LLC.
Funding involves a balanced mix of internal cash reserves and external borrowings.
💼 Action for Investors
Investors should view this as a positive step toward inorganic growth, with a clear and structured financing plan in place. Monitor the integration of Unbound Medicine and its contribution to the company's consolidated revenue and margins in upcoming quarters.
Oberoi Realty Emerges as Highest Bidder for Rs 5,400 Cr RLDA Land Parcel in Bandra East
Oberoi Realty has emerged as the highest bidder for a prime 11-acre (45,371 sq. mt.) land parcel in Bandra East, Mumbai, offered by the Railway Land Development Authority (RLDA). The company's bid stands at Rs 5,400 crore for a 99-year lease. The site offers a significant development potential of approximately 19.50 lakh sq. ft. of FSI. This acquisition, if finalized, will significantly bolster Oberoi's project pipeline in one of Mumbai's most premium micro-markets.
Key Highlights
Highest bid of Rs 5,400 crore for 11 acres of railway land in Bandra East
Total development potential of approximately 19.50 lakh sq. ft. of FSI
Lease period for the land development is set for 99 years
Strategic location adjoining the Western Express Highway in Mumbai
💼 Action for Investors
This is a major growth catalyst for the company's long-term NAV; investors should monitor for the formal Letter of Award and details on the funding strategy for this large capital outlay.
BMW Ventures Declares ₹1.50 Interim Dividend; Q3 Net Profit Rises 45% YoY to ₹11.50 Cr
BMW Ventures Limited reported a strong performance for Q3 FY26, with net profit increasing 44.9% year-on-year to ₹1,149.63 lakhs. Revenue from operations grew by 16% to ₹56,316.96 lakhs compared to the same quarter last year. In addition to the earnings growth, the Board declared an interim dividend of ₹1.50 per equity share (15% of face value). The company, which listed in October 2025, has already utilized ₹19,500 lakhs of its IPO proceeds, primarily for debt repayment, which has helped reduce finance costs.
Key Highlights
Net Profit grew 44.9% YoY to ₹1,149.63 lakhs in Q3 FY26 compared to ₹793.18 lakhs in Q3 FY25.
Revenue from operations increased to ₹56,316.96 lakhs from ₹48,489.91 lakhs in the previous year's quarter.
Interim dividend of ₹1.50 per share announced with a record date of February 10, 2026.
Basic EPS improved to ₹1.61 from ₹1.25 in the corresponding quarter of the previous year.
Company utilized ₹17,374.50 lakhs of IPO proceeds specifically for loan repayment as of December 31, 2025.
💼 Action for Investors
Investors should view the strong profit growth and immediate dividend payout post-listing as a sign of management's confidence in cash flows. The significant reduction in debt using IPO proceeds is a positive long-term driver for profitability.
BMW Ventures Q3 Net Profit Jumps 45% to ₹11.5 Cr; Declares ₹1.50 Interim Dividend
BMW Ventures Limited reported a strong Q3 FY26 performance with revenue from operations rising 16% YoY to ₹563.17 crore. Net profit for the quarter surged 45% to ₹11.50 crore, up from ₹7.93 crore in the same period last year. The Board declared an interim dividend of ₹1.50 per share, marking a positive return for shareholders following the company's October 2025 listing. Furthermore, the company has effectively utilized ₹173.75 crore of its IPO proceeds for debt repayment, significantly improving its financial position.
Key Highlights
Revenue from operations grew to ₹56,316.96 lakhs in Q3 FY26 compared to ₹48,489.91 lakhs in Q3 FY25.
Net profit increased to ₹1,149.63 lakhs for the quarter, representing a 44.9% growth year-on-year.
Declared an interim dividend of ₹1.50 per equity share (15% on face value of ₹10) with a record date of Feb 10, 2026.
Earnings Per Share (EPS) for the quarter improved to ₹1.61 from ₹1.25 in the previous year's corresponding quarter.
Successfully utilized ₹195 crore of IPO proceeds by Dec 31, 2025, including ₹173.75 crore for loan repayment.
💼 Action for Investors
The strong earnings growth and immediate dividend post-listing indicate robust operational health; investors may consider holding for long-term growth as debt levels reduce. Monitor the stock's performance around the February 10 record date for dividend eligibility.